HUP0300722A2 - Hidrogél segítségével szabályozott gyógyszerforma - Google Patents

Hidrogél segítségével szabályozott gyógyszerforma

Info

Publication number
HUP0300722A2
HUP0300722A2 HU0300722A HUP0300722A HUP0300722A2 HU P0300722 A2 HUP0300722 A2 HU P0300722A2 HU 0300722 A HU0300722 A HU 0300722A HU P0300722 A HUP0300722 A HU P0300722A HU P0300722 A2 HUP0300722 A2 HU P0300722A2
Authority
HU
Hungary
Prior art keywords
dosage form
core
hydrogel
drug dosage
water
Prior art date
Application number
HU0300722A
Other languages
English (en)
Inventor
Leah Elizabeth Appel
Walter C. Babcock
Ronald Arthur Beyerinck
Mark Brian Chidlaw
William John Curatolo
Dwayne Thomas Friesen
Scott Max Herbig
Avinash Govind Thombre
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of HUP0300722A2 publication Critical patent/HUP0300722A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány tárgyát egy ellenőrzött kibocsátású dózisforma képezi,amely rendelkezik egy bevont maggal, ahol a mag tartalmaz egygyógyszertartalmú összetételt és egy vízben duzzadó összetételt,amelyek mindegyike elkülönült teret foglal el a magon belül. A magotkörülvevő bevonat vízáteresztő, vízben oldhatatlan és legalább egyszállítónyílás található rajta. Számos geometriai elrendezéstárgyalása szerepel a leírásban. Ó
HU0300722A 2000-08-09 2001-08-03 Hidrogél segítségével szabályozott gyógyszerforma HUP0300722A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22419900P 2000-08-09 2000-08-09
PCT/IB2001/001390 WO2002011702A2 (en) 2000-08-09 2001-08-03 Hydrogel-driven drug dosage form

Publications (1)

Publication Number Publication Date
HUP0300722A2 true HUP0300722A2 (hu) 2003-11-28

Family

ID=22839665

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300722A HUP0300722A2 (hu) 2000-08-09 2001-08-03 Hidrogél segítségével szabályozott gyógyszerforma

Country Status (30)

Country Link
US (2) US20030086972A1 (hu)
EP (1) EP1326587A2 (hu)
JP (1) JP2004505907A (hu)
KR (1) KR20030024844A (hu)
CN (1) CN1461212A (hu)
AP (1) AP2001002237A0 (hu)
AU (1) AU2002229141A1 (hu)
BG (1) BG107538A (hu)
BR (1) BR0113067A (hu)
CA (1) CA2418907A1 (hu)
DO (1) DOP2001000229A (hu)
EA (1) EA200300081A1 (hu)
EC (1) ECSP034455A (hu)
EE (1) EE200300055A (hu)
GT (1) GT200100161A (hu)
HR (1) HRP20030082A2 (hu)
HU (1) HUP0300722A2 (hu)
IL (1) IL154012A0 (hu)
IS (1) IS6686A (hu)
MA (1) MA26939A1 (hu)
MX (1) MXPA03001209A (hu)
NO (1) NO20030627L (hu)
OA (1) OA12365A (hu)
PA (1) PA8524901A1 (hu)
PE (1) PE20020307A1 (hu)
PL (1) PL360658A1 (hu)
SV (1) SV2002000586A (hu)
TN (1) TNSN01123A1 (hu)
UY (1) UY26876A1 (hu)
WO (1) WO2002011702A2 (hu)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (en) 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
PL357535A1 (en) * 1999-12-23 2004-07-26 Pfizer Products Inc. Hydrogel-driven drug dosage form
AR030557A1 (es) 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US7964216B2 (en) 2001-01-12 2011-06-21 Sun Pharma Advanced Research Company Limited Spaced drug delivery system
EP1438018B1 (en) 2001-09-28 2010-08-11 McNeil-PPC, Inc. Fondant-based pharmaceutical composition
WO2003096968A2 (en) * 2002-05-15 2003-11-27 Sun Pharmaceutical Industries Limited Oral osmotic controlled drug delivery system
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
WO2004026241A2 (en) * 2002-09-20 2004-04-01 Andrx Labs Llc Multistage formulation containing a biguanide and thiazolidindione derivatives
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
EP1545452A1 (en) * 2002-09-28 2005-06-29 McNEIL-PPC, INC. Modified release dosage forms
US7807197B2 (en) 2002-09-28 2010-10-05 Mcneil-Ppc, Inc. Composite dosage forms having an inlaid portion
FR2850576B1 (fr) 2003-02-05 2007-03-23 Ethypharm Sa Composition comprenant un melange de principes actifs, et procede de preparation
US20060210633A1 (en) * 2003-04-03 2006-09-21 Sun Pharmaceutical Industries Limited Programmed drug delivery system
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
AR040157A1 (es) * 2003-06-06 2005-03-16 Rodriguez Julio Cesar Una formulacion en microgranulos para administracion oral en suspension acuosa
JP2007501217A (ja) * 2003-08-04 2007-01-25 ファイザー・プロダクツ・インク コレステリルエステル転送タンパク質阻害剤を制御放出し、そしてＨＭＧ−ＣｏＡレダクターゼ阻害剤を即時放出する投薬形態
US7879354B2 (en) 2004-01-13 2011-02-01 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
US8067029B2 (en) 2004-01-13 2011-11-29 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
EP1845953A1 (en) * 2005-02-03 2007-10-24 Pfizer Products Incorporated Dosage forms providing controlled and immediate release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
WO2006094083A1 (en) * 2005-02-28 2006-09-08 Penwest Pharmaceuticals Co. Controlled release venlafaxine formulations
US20080213381A1 (en) * 2005-03-14 2008-09-04 Pharmaceutical Industries Limited Oral Drug Delivery System
EP1858483A4 (en) * 2005-03-16 2009-07-15 Reddys Lab Ltd Dr SYSTEM FOR THE DELIVERY OF MULTIPLE MEDICAMENTS
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
CN100448433C (zh) * 2005-09-21 2009-01-07 广州贝氏药业有限公司 一种克拉霉素肠溶药物组合物
US20070248630A1 (en) * 2006-04-20 2007-10-25 Friden Phillip M Pharmaceutical formulations for iontophoretic methotrexate delivery
KR20080076382A (ko) * 2007-02-15 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
WO2009122431A2 (en) * 2008-02-15 2009-10-08 Sun Pharma Advanced Research Company Ltd., Oral controlled release tablet
US9333177B2 (en) * 2009-11-09 2016-05-10 Capsugel Belgium Nv Delivery carrier
ES2601884T3 (es) 2010-03-19 2017-02-16 Daiichi Sankyo Company, Limited Procedimiento para mejorar la capacidad de disolución de un anticoagulante
US9402907B2 (en) 2011-08-10 2016-08-02 Daiichi Sankyo Company, Limited Pharmaceutical composition containing diamine derivative
JP6284163B2 (ja) * 2013-01-30 2018-02-28 デウン カンパニー，リミテッド 胃腸管内における傷の保護、止血、または癒着の防止のための医薬組成物
MA41868A (fr) * 2015-04-01 2018-02-06 Spectrum Brands Inc Pastille retard et procédés s'y rapportant
WO2019173526A1 (en) * 2018-03-07 2019-09-12 Andrew Xian Chen Aqueous formulations for insoluble drugs
AR125988A1 (es) * 2021-05-28 2023-08-30 Amgen Inc Formulaciones de apremilast
CN113600179B (zh) * 2021-09-16 2023-07-04 山东博霖环保科技发展有限公司 一种脱硝催化剂及其制备方法
TW202325285A (zh) * 2021-10-14 2023-07-01 靜岡縣公立大學法人 粉末製劑

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1025765B (it) * 1974-11-18 1978-08-30 Gastaldi Francesco Essiccatore perfezionato a spruzzo
US4187617A (en) * 1978-12-18 1980-02-12 Becker James J Jr Spray dryer
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4449983A (en) * 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4624848A (en) * 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4851232A (en) * 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5612059A (en) * 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US5096716A (en) * 1988-09-01 1992-03-17 Alza Corporation Dosage form for administering calcium antagonist nicardipine
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
US5030452A (en) * 1989-01-12 1991-07-09 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
JPH05178763A (ja) * 1991-02-19 1993-07-20 Nippon Saafuakutanto Kogyo Kk 難溶解性薬物溶解剤組成物
MX9605419A (es) * 1994-05-06 1997-12-31 Pfizer Formas de dosificacion de liberacion controlada de azitromicina.
US5654005A (en) * 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
WO1999001120A1 (en) * 1997-07-01 1999-01-14 Pfizer Products Inc. Solubilized sertraline compositions
KR100446366B1 (ko) * 1997-07-01 2004-09-01 화이자 인코포레이티드 서트랄린 염 및 서트랄린의 서방성 투여형
DE19747261A1 (de) * 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
CA2346335C (en) * 1998-10-13 2006-04-18 Pfizer Products Inc. Sertraline oral concentrate
ATE433318T1 (de) * 1999-02-10 2009-06-15 Pfizer Prod Inc Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
AR028253A1 (es) * 2000-03-16 2003-04-30 Pfizer Prod Inc Inhibidores de la glucogeno fosforilasa
EP1572163A1 (en) * 2002-12-11 2005-09-14 Pfizer Products Inc. Controlled-release of an active substance into a high fat environment

Also Published As

Publication number Publication date
GT200100161A (es) 2002-03-22
WO2002011702A2 (en) 2002-02-14
US20030086972A1 (en) 2003-05-08
JP2004505907A (ja) 2004-02-26
CA2418907A1 (en) 2002-02-14
KR20030024844A (ko) 2003-03-26
EP1326587A2 (en) 2003-07-16
EA200300081A1 (ru) 2003-08-28
OA12365A (en) 2006-05-16
SV2002000586A (es) 2002-10-24
MA26939A1 (fr) 2004-12-20
IS6686A (is) 2003-01-16
NO20030627L (no) 2003-04-08
NO20030627D0 (no) 2003-02-07
AU2002229141A1 (en) 2002-02-18
DOP2001000229A (es) 2002-09-30
MXPA03001209A (es) 2003-06-30
IL154012A0 (en) 2003-07-31
HRP20030082A2 (en) 2003-04-30
TNSN01123A1 (fr) 2005-11-10
PA8524901A1 (es) 2002-04-25
AP2001002237A0 (en) 2001-09-30
CN1461212A (zh) 2003-12-10
BG107538A (bg) 2003-11-28
ECSP034455A (es) 2003-03-10
WO2002011702A3 (en) 2002-11-28
UY26876A1 (es) 2002-03-22
EE200300055A (et) 2004-12-15
PE20020307A1 (es) 2002-04-23
BR0113067A (pt) 2003-07-01
US20040052845A1 (en) 2004-03-18
PL360658A1 (en) 2004-09-20

Similar Documents

Publication Publication Date Title
HUP0300722A2 (hu) Hidrogél segítségével szabályozott gyógyszerforma
WO2004056337A3 (en) Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
AP2002002553A0 (en) Hydrogel-driven Drug Dosoge Form.
NO20016108D0 (no) Kontrollert frigivelse og smaks maskerende orale farmasöytiske sammensetninger
HUP0101437A2 (hu) Elnyújtott hatóanyag-kibocsátási formájú orális gyógyszerkészítmény
ATE320799T1 (de) Retardierte, orale, pharmazeutische darreichnungsformen mit tramadol
BR9801989A (pt) Pellets entéricos de fluoxetina.
HUP0401191A2 (hu) Opioid agonistát, valamint leadható és álcázott antagonistát tartalmazó készítmények
MX9706769A (es) Formas de dosificacion farmaceutica que comprenden un inhibidor de la bomba de protones y un agente procinetico.
HUP0203623A2 (hu) Tramadol-szacharinátot tartalmazó, késleltetett hatású adagolási forma és alkalmazása
PT797991E (pt) Formulacao com libertacao prolongada contendo venlafaxina
DE69925639D1 (de) Glicazidhaltige matrixtablette mit verzögerter wirkstoffverabreichung zur oralen anwendung
NO20011085D0 (no) Tablett med umiddelbar frigivningsvirkning
IS7065A (is) Áætlun um lyfjaskammta við meðferð og lyfjasamsetningar til getnaðarvarna í neyð
DE60235648D1 (de) Pharmazeutische metformintablette mit verlängerter freisetzung
NO20022645D0 (no) Farmasöytisk superdisintegrerende stoff
TR199902175T2 (xx) Parasetamol i�eren yutma tableti.
HUP0004015A2 (hu) Három különböző, egyenként legalább egy hatóanyagot tartalmazó rétegből álló monolitikus, orális rendszer
ITMI20022292A1 (it) 9a-azalidi ad attivita' antiinfiammatoria.
HUP0000137A2 (hu) Szabályozott hatóanyag-felszabadulású analgetikumot tartalmazó gyógyszerkészítmény
CL2007003010A1 (es) Forma de dosificacion oral que comprende un nucleo erosionable que contiene un principio activo de caracter basico debil, un recubrimiento erosionable en torno a dicho nucleo con una o mas abertura que atraviesn el recubrimiento y conectan al nucleo con el medio de uso; procedimiento de preparacion; y uso (divisional de 260-03).
ATE304844T1 (de) Entzündungshemmende pharmazeutische formulierungen
BRPI0412697A (pt) composições farmacêuticas que apresentam um revestimento expansìvel
PA8523101A1 (es) Composicion de eletriptan en forma de particulas
AR028448A1 (es) Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares